Amid shortages of cancer drugs in the U.S., the API Innovation Center will use continuous manufacturing technology and a partnership with Apertus Pharmaceuticals and the Glioblastoma Foundation to ...

Outsource API manufacturing to India for lower costs, GMP-compliant quality, scalable production, and faster time-to-market for pharma companies.

Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.